These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

331 related articles for article (PubMed ID: 32816947)

  • 1. Coexpression of IL7 and CCL21 Increases Efficacy of CAR-T Cells in Solid Tumors without Requiring Preconditioned Lymphodepletion.
    Luo H; Su J; Sun R; Sun Y; Wang Y; Dong Y; Shi B; Jiang H; Li Z
    Clin Cancer Res; 2020 Oct; 26(20):5494-5505. PubMed ID: 32816947
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interleukin-7-loaded oncolytic adenovirus improves CAR-T cell therapy for glioblastoma.
    Huang J; Zheng M; Zhang Z; Tang X; Chen Y; Peng A; Peng X; Tong A; Zhou L
    Cancer Immunol Immunother; 2021 Sep; 70(9):2453-2465. PubMed ID: 33543339
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhanced anti-tumor efficacy of IL-7/CCL19-producing human CAR-T cells in orthotopic and patient-derived xenograft tumor models.
    Goto S; Sakoda Y; Adachi K; Sekido Y; Yano S; Eto M; Tamada K
    Cancer Immunol Immunother; 2021 Sep; 70(9):2503-2515. PubMed ID: 33559069
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Preliminary study of the fourth-generation CAR-T cells targeting CS1 in the treatment of refractory and recurrent multiple myeloma].
    Feng DD; Chen XH; Guo JJ; Wang KK; Zhang XM; Gao JM
    Zhonghua Zhong Liu Za Zhi; 2021 Jun; 43(6):657-665. PubMed ID: 34289557
    [No Abstract]   [Full Text] [Related]  

  • 5. Constitutive Signaling from an Engineered IL7 Receptor Promotes Durable Tumor Elimination by Tumor-Redirected T Cells.
    Shum T; Omer B; Tashiro H; Kruse RL; Wagner DL; Parikh K; Yi Z; Sauer T; Liu D; Parihar R; Castillo P; Liu H; Brenner MK; Metelitsa LS; Gottschalk S; Rooney CM
    Cancer Discov; 2017 Nov; 7(11):1238-1247. PubMed ID: 28830878
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Claudin18.2-Specific Chimeric Antigen Receptor Engineered T Cells for the Treatment of Gastric Cancer.
    Jiang H; Shi Z; Wang P; Wang C; Yang L; Du G; Zhang H; Shi B; Jia J; Li Q; Wang H; Li Z
    J Natl Cancer Inst; 2019 Apr; 111(4):409-418. PubMed ID: 30203099
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel chimeric antigen receptor containing a JAK-STAT signaling domain mediates superior antitumor effects.
    Kagoya Y; Tanaka S; Guo T; Anczurowski M; Wang CH; Saso K; Butler MO; Minden MD; Hirano N
    Nat Med; 2018 Mar; 24(3):352-359. PubMed ID: 29400710
    [TBL] [Abstract][Full Text] [Related]  

  • 8. T cell engineered with a novel nanobody-based chimeric antigen receptor against VEGFR2 as a candidate for tumor immunotherapy.
    Hajari Taheri F; Hassani M; Sharifzadeh Z; Behdani M; Arashkia A; Abolhassani M
    IUBMB Life; 2019 Sep; 71(9):1259-1267. PubMed ID: 30724452
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Construction and function of Glypican-3-targeted fourth-generation chimeric antigen receptor T cells (secreting IL-7 and CCL19)].
    Huang W; Liu Y; Hu Y; Gao J
    Sheng Wu Gong Cheng Xue Bao; 2020 May; 36(5):979-991. PubMed ID: 32567281
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination of AAV-CCL19 and GPC3 CAR-T Cells in the Treatment of Hepatocellular Carcinoma.
    Meng M; Wu YC
    J Immunol Res; 2021; 2021():1782728. PubMed ID: 34527749
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IL7-IL12 Engineered Mesenchymal Stem Cells (MSCs) Improve A CAR T Cell Attack Against Colorectal Cancer Cells.
    Hombach AA; Geumann U; Günther C; Hermann FG; Abken H
    Cells; 2020 Apr; 9(4):. PubMed ID: 32260097
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CXCL9-modified CAR T cells improve immune cell infiltration and antitumor efficacy.
    Tian Y; Wen C; Zhang Z; Liu Y; Li F; Zhao Q; Yao C; Ni K; Yang S; Zhang Y
    Cancer Immunol Immunother; 2022 Nov; 71(11):2663-2675. PubMed ID: 35352167
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined CD28 and 4-1BB Costimulation Potentiates Affinity-tuned Chimeric Antigen Receptor-engineered T Cells.
    Drent E; Poels R; Ruiter R; van de Donk NWCJ; Zweegman S; Yuan H; de Bruijn J; Sadelain M; Lokhorst HM; Groen RWJ; Mutis T; Themeli M
    Clin Cancer Res; 2019 Jul; 25(13):4014-4025. PubMed ID: 30979735
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adoptive Transfer of IL13Rα2-Specific Chimeric Antigen Receptor T Cells Creates a Pro-inflammatory Environment in Glioblastoma.
    Pituch KC; Miska J; Krenciute G; Panek WK; Li G; Rodriguez-Cruz T; Wu M; Han Y; Lesniak MS; Gottschalk S; Balyasnikova IV
    Mol Ther; 2018 Apr; 26(4):986-995. PubMed ID: 29503195
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PTK7-Targeting CAR T-Cells for the Treatment of Lung Cancer and Other Malignancies.
    Jie Y; Liu G; Feng L; Li Y; E M; Wu L; Li Y; Rong G; Li Y; Wei H; Gu A
    Front Immunol; 2021; 12():665970. PubMed ID: 34475869
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemokine Receptor CCR2b Enhanced Anti-tumor Function of Chimeric Antigen Receptor T Cells Targeting Mesothelin in a Non-small-cell Lung Carcinoma Model.
    Wang Y; Wang J; Yang X; Yang J; Lu P; Zhao L; Li B; Pan H; Jiang Z; Shen X; Liang Z; Liang Y; Zhu H
    Front Immunol; 2021; 12():628906. PubMed ID: 33777013
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regional Delivery of Chimeric Antigen Receptor-Engineered T Cells Effectively Targets HER2
    Priceman SJ; Tilakawardane D; Jeang B; Aguilar B; Murad JP; Park AK; Chang WC; Ostberg JR; Neman J; Jandial R; Portnow J; Forman SJ; Brown CE
    Clin Cancer Res; 2018 Jan; 24(1):95-105. PubMed ID: 29061641
    [No Abstract]   [Full Text] [Related]  

  • 18. Lenalidomide Enhances the Function of CS1 Chimeric Antigen Receptor-Redirected T Cells Against Multiple Myeloma.
    Wang X; Walter M; Urak R; Weng L; Huynh C; Lim L; Wong CW; Chang WC; Thomas SH; Sanchez JF; Yang L; Brown CE; Pichiorri F; Htut M; Krishnan AY; Forman SJ
    Clin Cancer Res; 2018 Jan; 24(1):106-119. PubMed ID: 29061640
    [No Abstract]   [Full Text] [Related]  

  • 19. Interleukin-23 engineering improves CAR T cell function in solid tumors.
    Ma X; Shou P; Smith C; Chen Y; Du H; Sun C; Porterfield Kren N; Michaud D; Ahn S; Vincent B; Savoldo B; Pylayeva-Gupta Y; Zhang S; Dotti G; Xu Y
    Nat Biotechnol; 2020 Apr; 38(4):448-459. PubMed ID: 32015548
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CAIX-specific CAR-T Cells and Sunitinib Show Synergistic Effects Against Metastatic Renal Cancer Models.
    Li H; Ding J; Lu M; Liu H; Miao Y; Li L; Wang G; Zheng J; Pei D; Zhang Q
    J Immunother; 2020 Jan; 43(1):16-28. PubMed ID: 31574023
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.